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Abstract
Background: Interactions between the gene products encoded by the mitochondrial and nuclear
genomes play critical roles in eukaryotic cellular function. However, the effects mitochondrial DNA
(mtDNA) levels have on the nuclear transcriptome have not been defined under physiological
conditions. In order to address this issue, we characterized the gene expression profiles of A549
lung cancer cells and their mtDNA-depleted ρ0 counterparts grown in culture and as tumor
xenografts in immune-deficient mice.
Results:  Cultured A549 ρ0 cells were respiration-deficient and showed enhanced levels of
transcripts relevant to metal homeostasis, initiation of the epithelial-mesenchymal transition, and
glucuronidation pathways. Several well-established HIF-regulated transcripts showed increased or
decreased abundance relative to the parental cell line. Furthermore, growth in culture versus
xenograft has a significantly greater influence on expression profiles, including transcripts involved
in mitochondrial structure and both aerobic and anaerobic energy metabolism. However, both in
vitro and in vivo, mtDNA levels explained the majority of the variance observed in the expression
of transcripts in glucuronidation, tRNA synthetase, and immune surveillance related pathways.
mtDNA levels in A549 xenografts also affected the expression of genes, such as AMACR and PHYH,
involved in peroxisomal lipid metabolic pathways.
Conclusion: We have identified mtDNA-dependent gene expression profiles that are shared in
cultured cells and in xenografts. These profiles indicate that mtDNA-depleted cells could provide
informative model systems for the testing the efficacy of select classes of therapeutics, such as anti-
angiogenesis agents. Furthermore, mtDNA-depleted cells grown culture and in xenografts provide
a powerful means to investigate possible relationships between mitochondrial activity and gene
expression profiles in normal and pathological cells.
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Background
The discovery that mammalian cells grown in the pres-
ence of inhibitors of mitochondrial DNA (mtDNA) repli-
cation and transcription can lose all or almost all their
mtDNA has provided a powerful means to study interac-
tions between the mitochondrial and nuclear genomes,
reviewed in [1-4]. The human mitochondrial genome is
16,569-bp in length and encodes 12S and 16S rRNAs, 22
tRNAs, and 13 polypeptides involved in the respiratory
electron transport chain and ATP synthesis. The compre-
hensive MitoP2 database of human mitochondrial pro-
teins http://www.mitop.de:8080/mitop2/
showhumanmask.do   lists 870 human mitochondrial
proteins encoded by the nuclear genome [5]. Proteomic
and systems biology approaches will likely unearth addi-
tional proteins directly involved in human mitochondrial
function [6]. However, fundamental questions will
remain about the influences mtDNA has on the regulation
of nuclear genes in vivo.
mtDNA-depleted ρ0 cell lines are auxotrophic for pyruvate
and uridine, and are incapable of aerobic respiration due
to the lack of key respiratory chain components [7,8].
Nonetheless, mtDNA-depleted cell lines possess distorted
mitochondria-like structures comprised of nuclear-
encoded mitochondrial proteins [9-11] and demonstrate
increased invasive behavior in culture [12-17] Further-
more, mtDNA-depleted cells can grow as tumor
xenografts in immune-deficient mice in some instances
[18,19], but not others [20].
Here, we generated mtDNA-depleted A549 ρ0 lung cancer
cells and validated their genetic and biochemical proper-
ties in culture and tumor xenografts. Our gene expression
profiling analyses of parental A549 and A549 ρ0 cells
uncovered differential expression of transcripts relevant to
immune recognition, autophagy of defective mitochon-
dria, HIF-mediated gene regulation, the epithelial-mesen-
chymal transition (EMT), and elimination of lipophilic
molecules. Furthermore, growth in culture versus in
xenograft had a greater effect on the A549 transcriptome,
especially nuclear-encoded genes important for mito-
chondrial function and energy metabolism, than the pres-
ence of mtDNA. Overall, mtDNA-depleted cells grown in
culture and in xenograft provide complementary means to
identify relationships between mitochondrial activity and
cellular gene expression profiles that could serve as poten-
tial biomarkers of disease.
Methods
Cells and cell culture reagents
A549 lung cancer cells were obtained from the American
Type Culture Collection. Unless otherwise indicated, all
cell culture reagents were purchased from Invitrogen.
mtDNA-deficient A549 ρ0 cell cultures were prepared by
serial passage of parental A549 cells for 28 population
doublings in standard growth media (RPMI 1640
medium supplemented with 20 mM HEPES, 2 mM L-
glutamine, 10% heat inactivated fetal bovine serum
(Hyclone), 200 U/mL penicillin, and 200 μg/mL strepto-
mycin) in the presence of ethidium bromide (100 ng/
mL), sodium pyruvate (1 mM), and uridine (50 μg/mL).
The glucose concentration in the standard growth media
is approximately 11 mM. All subsequent experiments
employing A549 and A549 ρ0 cell cultures were conducted
in the same standard growth media supplemented only
with sodium pyruvate (1 mM) and uridine (50 μg/mL).
Growth curves were obtained by Coulter counting. All
experiments were conducted using cell culture popula-
tions and not purified clones.
Estimation of mtDNA levels
mtDNA levels in A549 or A549 ρ0 cell cultures were esti-
mated using the pseudogene ratioing method [21].
Briefly, total DNA (both mitochondrial and genomic) was
extracted from A549 or A549 ρ0 cell cultures using the
QIAamp DNA Mini Kit (Qiagen). These served as tem-
plates for PCR amplification using primers designed to
anneal either to mtDNA or a previously described DNA-
embedded mtDNA pseudogene (mtDNAψ) [22]. Ampli-
cons derived from either nuclear DNA-embedded mtDNA
pseudogene or mtDNA templates are predicted to be
approximately the same length, but differ in sequence.
These amplicons served as templates for a nested PCR
using primers designed to amplify both the mtDNA-
encoded MT-CO2 and the nuclear DNA-embedded mtD-
NAψ sequences. The resulting amplicons were subcloned
using the StrataClone™ PCR cloning system (Stratagene).
Plasmid DNA from individual colonies was prepared for
sequencing using the illustra TempliPhi 100/500 DNA
Amplification Kit (GE Healthcare). The resulting products
were sequenced using BigDye Terminator v3.0 from
Applied Biosystems diluted with halfBD (Genetix Ltd.),
according to manufacturer's recommendations. We
obtained sequence information from 70 colonies derived
from A549 DNA templates (all showed mtDNA
sequences) and 92 colonies derived from A549 ρ0 DNA
templates (all showed mtDNAψ sequences). mtDNA
abundance in the original A549 or A549 ρ0 DNA prepara-
tion was estimated based on the number of colonies
showing mtDNA or mtDNAψ sequences, as previously
described [21].
Oxygen consumption
Oxygen consumption rates were measured using a Clark-
type electrode [23]. In brief, plateau phase cultures of
A549 or A549 ρ0 cells were treated with antimycin A (1 μg/
mL) or control vehicle for 3 hours. After medium was
removed, cells were washed with Hanks balanced salt
solution (HBSS), and harvested using trypsin/EDTA. CellsBMC Genomics 2008, 9:521 http://www.biomedcentral.com/1471-2164/9/521
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were resuspended in complete medium, stored on ice, and
aliquots were removed for Coulter counting and viability
(defined as ability to exclude propidium iodide). Prior to
measurement, an aliquot of cell suspension (ca. 1 × 107
cells/mL) was incubated at 37°C for 2 minutes, and then
transferred to the sealed electrode chamber of an
Oxytherm apparatus (Hansatech, Norfolk, UK) to meas-
ure dissolved oxygen concentration. Background oxygen
consumption by the electrode in the absence of cells was
subtracted from all measurements.
Quantitative RT-PCR analysis
RNA was obtained from cultured A549 cells or harvested
from tumor specimens as described [24]. Total RNA was
quantified using the Ribogreen RNA quantitation kit
(Molecular Probes). One-step RT-PCR assays were set up
in triplicate according to manufacturer's instructions
using the Taqman master mix (Applied Biosystems, Inc.)
and 50 ng of total RNA as template. The amount of RNA
in each well was re-quantified and used for normaliza-
tions. Gene expression assay probe sets for β-actin, MT-
ATP6, and MT-CYB were purchased from Applied Biosys-
tems and assays were performed on an ABI PRISM 7300
instrument according to standard protocols.
ELISA and Western blotting
Total HIF-1a protein was detected by sandwich ELISA
using the DuoSet IC™ HIF-1a ELISA kit obtained from
R&D Systems. Briefly, 96-well plates were coated with
HIF-1a capture antibody overnight prior to blocking with
5% BSA in wash buffer. Protein lysates (50 μg protein per
well prepared according to the manufacturer's instruc-
tions) were added for 2 hours, whereupon plates were
washed and a biotinylated detection antibody specific for
HIF-1a was added. A streptavidin-horseradish peroxidase
format was used for detection. The optical density at 450
minus 570 nm was measured using a microplate reader
(SpectraMax Plus). HIF-1a concentrations were calculated
by linear regression using a standard curve prepared from
HIF-1a standard supplied with the ELISA kit.
Western blotting was performed using antibodies against
GLUT1 (aka SLC2A1, rabbit polyclonal), PGK1 (goat pol-
yclonal), MTCO2 (mouse monoclonal), PDK1 (rabbit
polyclonal), and DDIT4 (rabbit polyclonal) obtained
from Santa Cruz Biotechnology, Molecular Probes, Stress-
gen, and Proteintech, respectively. All membranes were
blotted with an anti-Hsc70 (mouse monoclonal, Santa
Cruz Biotechnology) antibody to control for loading and
transfer. HRP-conjugated goat anti-rabbit and goat anti-
mouse secondary antibodies were from Pierce. HRP-con-
jugated donkey anti-goat secondary antibody was from
Santa Cruz Biotechnology. HRP substrate was from Pierce.
Bands were imaged and quantified in the linear range and
normalized to Hsc70, using the ChemiDoc XRS Imaging
System (BioRad Laboratories, Inc.).
Gene expression profiling in cell culture
A549 or A549 ρ0 human lung cancer cells (1 × 105 cells per
T-25 flask in 7 mL complete RPMI 1640 medium) were
seeded 8 days prior to RNA isolation. Each experiment
was performed in triplicate. After incubation, all cultures
were washed twice with HBSS supplemented with 0.5%
BSA and total RNA was isolated and subjected to analysis
on Human Genome U133A Arrays (Affymetrix), as
described [24,25]. ArrayAssist software (Stratagene) was
used to generate scaled log2 transformed gene expression
scores based on the RMA algorithm and to conduct hier-
archical clustering analyses, as previously described [24].
Probe sets with a > 1.5-fold differential expression (two-
tailed Student's t-test P < 0.01 subjected to Benjamini and
Hochberg correction for multiple comparisons, and > 20
unit difference in the geometric mean expression scores)
in a comparison of interest are reported.
We used analysis of variance to estimate the proportion of
variance explained by mtDNA status and explained by
growth conditions, in the gene expression profiles from
A549 ρ0 and parental A549 cells grown in culture and in
xenografts. Statistical significance is determined using the
Bayes Moderated F test [26] implemented using the
limma package in Bioconductor [27]. This uses an empir-
ical Bayes approach, providing more stable inference
when the number of arrays is small. P-values are adjusted
for multiple comparisons using the Benjamini and Hoch-
berg approach to control the false-discovery rate [28].
GeneOntology and KEGG analyses were conducted using
WebGestalt software http://bioinfo.vanderbilt.edu/web
gestalt/[29-31]. All scaled fluorescent intensity values and
.cel files are available at the National Center for Biotech-
nology Information (NCBI) Gene Expression Omnibus
(GEO) repository http://www.ncbi.nlm.nih.gov/geo/
under Series Accession Number GSE10957. In addition,
all scaled fluorescent intensity values are available in Sup-
plemental Table 1.
Gene expression profiling in mouse xenograft models
Animal care was in accordance with NIH and institutional
guidelines. For the A549 xenograft model, 1.7 million
A549 cells were injected subcutaneously/intramuscularly
into the right hind flank of 6 week old CD-1 nude mice
that had been irradiated with 4 Gy of total body irradia-
tion from a 137Cs radiation source one day prior to tumor
implantation [32]. For the A549 ρ0 xenograft model, 1.5
million cells were used. Tumor and body weight measure-
ments (6 or 7 mice per group) were performed three times
per week once tumors became palpable. This occurred 41
versus 9 days post-implantation in ρ0 and parental A549B
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Table 1: Transcripts where 90% of the variance in gene expression is explained by mtDNA status
Affymetrix Probe 
ID
Gene Symbol Entrez GeneID Gene Description ρ0 Proportion of 
Variancea
F testb ρ0 Vitro/A549 Vitro ρ0 Vivo/A549 
Vivo
FCc Pd FCc Pd
Up-regulated in 
ρ0 cells
214247_s_at DKK3 27122 dickkopf homolog 3 0.98 8.62 × 10-11 4.4 0.0009 3.7 0.0005
209822_s_at VLDLR 7436 very low density lipoprotein 
receptor
0.98 7.05 × 10-10 3.3 0.0057 2.7 0.0002
210105_s_at FYN 2534 FYN oncogene 0.97 9.85 × 10-9 3.4 0.0082 2.7 0.0009
221305_s_at UGT1A8 54576 UDP glucuronosyltransferase 1 
family
0.97 1.21 × 10-8 8.3 0.0088 13.1 0.0007
202242_at TSPAN7 7102 tetraspanin 7 0.96 3.45 × 10-11 9.3 0.0046 9.3 0.0005
205119_s_at FPR1 2357 formyl peptide receptor 1 0.96 3.82 × 10-9 3.8 0.0045 4.8 0.0010
208596_s_at UGT1A10 54575 UDP glucuronosyltransferase 1 
family
0.96 1.20 × 10-10 6.2 0.0051 10.2 0.0001
219093_at PID1 55022 hypothetical protein FLJ20701 0.95 1.41 × 10-8 5.4 0.0090 4.2 0.0020
209040_s_at PSMB8 5696 proteasome subunit 0.95 2.73 × 10-10 3.2 0.0048 2.9 0.0003
206094_x_at UGT1A6 54578 UDP glucuronosyltransferase 1 
family
0.95 6.79 × 10-11 5.9 0.0041 9.7 0.0001
219959_at PTHLH 55034 parathyroid hormone-like hormone 0.94 2.77 × 10-9 2.8 0.0079 3.1 0.0005
201042_at TGM2 7052 transglutaminase 2 0.94 1.64 × 10-6 1.6 0.0245 1.6 0.0014
207126_x_at UGT1A4 54657 UDP glucuronosyltransferase 1 
family
0.93 3.45 × 10-11 6.7 0.0048 11.5 0.0000
203113_s_at EEF1D 1936 eukaryotic translation elongation 
factor
0.92 1.10 × 10-5 1.5 0.0291 1.6 0.0042
204802_at RRAD 6236 Ras-related associated with diabetes 0.92 9.09 × 10-7 2.5 0.0289 2.7 0.0044
215125_s_at UGT1A10 54575 UDP glucuronosyltransferase 1 
family
0.92 8.62 × 10-11 7.2 0.0045 12.7 0.0001
213587_s_at ATP6V0E2 155066 ATPase, H+ transporting V0 subunit 
e2
0.92 3.60 × 10-6 1.7 0.0447 1.9 0.0021
217739_s_at PBEF1 10135 pre-B-cell colony enhancing factor 1 0.91 4.54 × 10-7 3.8 0.0141 11.0 0.0004
204532_x_at UGT1A4 54657 UDP glucuronosyltransferase 1 
family
0.91 3.96 × 10-10 5.8 0.0055 10.9 0.0000
212160_at XPOT 11260 exportin, tRNA 0.91 1.52 × 10-5 1.6 0.0524 1.9 0.0015
212307_s_at OGT 8473 GlcNAc transferase 0.91 6.52 × 10-7 1.7 0.0273 2.4 0.0007
203262_s_at FAM50A 9130 family with sequence similarity 50 0.91 3.01 × 10-5 1.5 0.0435 1.6 0.0030
217738_at PBEF1 10135 pre-B-cell colony enhancing factor 1 0.91 1.76 × 10-7 4.5 0.0054 11.2 0.0007
201462_at SCRN1 9805 secernin 1 0.90 2.79 × 10-5 1.4 0.0186 1.5 0.0032
219762_s_at RPL36 25873 ribosomal protein L36 0.90 8.04 × 10-6 1.4 0.0073 1.7 0.0014
212909_at LYPD1 116372 LY6/PLAUR domain containing 1 0.90 1.04 × 10-5 2.5 0.0069 1.7 0.0050
215025_at NTRK3 4916 neurotrophic tyrosine kinase, 
receptor
0.90 6.53 × 10-7 2.6 0.0179 2.2 0.0048
201474_s_at ITGA3 3675 integrin, alpha 3 0.90 1.57 × 10-6 1.8 0.0491 1.8 0.0018
Down-regulated 
in ρ0 cells
211600_at MT-ND5 4540 mito. encoded NADH 
dehydrogenase 5
0.99 4.48 × 10-14 -73.7 0.0007 -46.9 0.0001
205674_x_at FXYD2 486 FXYD domain ion transport 
regulator 2
0.98 3.45 × 10-11 -11.0 0.0029 -14.8 0.0004B
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211203_s_at CNTN1 1272 contactin 1 0.97 4.65 × 10-9 -4.7 0.0009 -3.6 0.0015
204698_at ISG20 3669 interferon stimulated exonuclease 
gene
0.96 3.67 × 10-8 -3.5 0.0056 -2.9 0.0014
210065_s_at UPK1B 7348 uroplakin 1B 0.95 4.17 × 10-8 -4.3 0.0071 -6.2 0.0013
203108_at GPRC5A 9052 G protein-coupled receptor 0.95 4.96 × 10-9 -3.4 0.0048 -5.9 0.0001
207434_s_at FXYD2 4151 FXYD domain ion transport 
regulator 2
0.95 2.29 × 10-11 -9.8 0.0063 -12.9 0.0003
201065_s_at GTF2I 2969 general transcription factor II, i 0.95 6.30 × 10-7 -2.0 0.0109 -1.7 0.0010
210064_s_at UPK1B 7348 uroplakin 1B 0.95 1.51 × 10-8 -5.8 0.0081 -5.9 0.0020
222088_s_at SLC2A3 6515 solute carrier family 2, member 3 0.95 1.46 × 10-8 -2.1 0.0080 -2.4 0.0010
33304_at ISG20 3669 interferon stimulated exonuclease 
gene
0.95 3.70 × 10-7 -2.9 0.0077 -2.4 0.0036
218995_s_at EDN1 1906 endothelin 1 0.94 3.16 × 10-7 -2.2 0.0333 -2.7 0.0014
219045_at RHOF 54509 ras homolog gene family, member F 0.93 4.81 × 10-7 -2.9 0.0062 -2.0 0.0018
214774_x_at TNRC9 27324 trinucleotide repeat containing 9 0.93 4.39 × 10-7 -2.9 0.0109 -3.9 0.0027
206291_at NTS 4922 neurotensin 0.93 6.81 × 10-8 -102 0.0009 -17.9 0.0011
201909_at RPS4Y1 6192 ribosomal protein S4, Y-linked 1 0.92 3.55 × 10-8 -5.8 0.0071 -18.8 0.0000
206700_s_at JARID1D 8284 jumonji, AT rich interactive domain 
1D
0.90 2.41 × 10-7 -2.3 0.0366 -4.0 0.0000
203043_at ZBED1 9189 zinc finger, BED-type containing 1 0.90 6.01 × 10-6 -1.7 0.0427 -1.9 0.0026
202499_s_at SLC2A3 6515 solute carrier family 2, member 3 0.90 2.86 × 10-6 -1.9 0.0128 -2.3 0.0073
216623_x_at TNRC9 27324 trinucleotide repeat containing 9 0.90 5.79 × 10-7 -2.6 0.0128 -3.5 0.0038
aProportion of variance in gene expression due to mtDNA status in cultured cells and xenografts
bBayes modified F test (multiple hypothesis corrected)
cFold-change
dBenjamini and Hochberg corrected two-tailed Student's t-test
Table 1: Transcripts where 90% of the variance in gene expression is explained by mtDNA status (Continued)BMC Genomics 2008, 9:521 http://www.biomedcentral.com/1471-2164/9/521
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xenograft models, respectively. Tumor volume was calcu-
lated using the equation V (mm3) = a × b2/2, where a is the
largest diameter and b is the smallest diameter. No signif-
icant body weight loss was observed. To perform gene
expression profiling, tumors (4 tumors per group) were
harvested and snap frozen immediately on dry ice when
the tumor size reached 500–800 mm3. Tumor tissue was
dissected, homogenized in Trizol, and total RNA was iso-
lated and subjected to gene expression analysis as
described above.
Additional Files
Additional information about the data reported in this
manuscript, including formatted gene expression data in
these studies are available at BMC Genomics.
Results and discussion
Establishment of A549 ρ0 cell cultures
Candidate A549 ρ0 lung cancer cell cultures were prepared
using previously described ethidium bromide-based pro-
tocols [12]. Consistent with prior reports of ρ0 cell lines
(e.g. [7,9,33]), the resulting cells displayed auxotrophic
growth dependence on pyruvate and uridine and elon-
gated shape (data not shown). The growth rate of the can-
didate ρ0 cells (27 hour generation time) was slower than
the parental line (20 hour generation time) in pyruvate
and uridine supplemented medium (Fig. 1A).
We used the recently described pseudo-gene ratioing tech-
nique to estimate the amount of mtDNA remaining in the
candidate A549 ρ0 cell cultures (Methods) [21]. This tech-
nique is based on quantifying the relative co-amplifica-
tion of a mtDNA sequence and a nuclear-embedded
mitochondrial pseudogene (mtDNAψ) sequence [22]
using total DNA extracted from candidate A549 ρ0 cells
and parental A549 cells. Assuming the mtDNAψ sequence
is present in two copies per candidate A549 ρ0 cell, we
could estimate with 95% confidence that the candidate
A549  ρ0 cell cultures contained less than one copy of
mtDNA per 14 cells. As a positive control, we used the
same technique to estimate that a minimum of 45
mtDNA copies were extracted from each parental A549
cell (exact binomial upper 95% confidence limit). As a
consequence of these observations, as well other bio-
chemical characterizations described below, we will here-
after refer to the candidate A549 ρ0 cell cultures as A549
ρ0cells.
Cultured A549 ρ0 cells have impaired rates of oxygen 
consumption
To characterize mitochondrial function in the parental
A549 and A549 ρ0 cells, we compared their rates of oxygen
consumption. As expected, parental A549 cells showed
robust oxygen consumption while the oxygen consump-
tion of the A549 ρ0 cells was indistinguishable (P = 0.41)
from background (Fig. 1B). To demonstrate the involve-
ment of respiration, we also treated parental A549 and
A549 ρ0 cells with antimycin A, an inhibitor of mitochon-
drial complex III of the electron transport chain (ETC)
[34], prior to measuring oxygen consumption. As
expected, antimycin A-treated A549 cells showed reduced
oxygen consumption, while A549 ρ0 cells were not signif-
icantly affected by drug-treatment (Fig. 1B). These results
strongly suggest that residual mitochondria-dependent
aerobic respiration in A549 ρ0 cells, if present, is below the
threshold that can be measured in this assay.
A549 ρ0 cells grow in tumor xenografts at a slower rate 
than their parental cells
Parental A549 cells and their ρ0 derivatives both grew as
xenografts when implanted shallowly (subcutaneously/
intramuscularly) in the flank muscle of nude mice.
mtDNA-depleted cell lines have been reported to form
xenograft tumors [13,18,19]. Here, we found that A549 ρ0
cells grow readily in xenograft, although at a slower rate
and after a longer induction period (approximately 30
days) relative to the parental line (Fig. 2). This is consist-
ent with the growth characteristics of tumor xenografts
derived from N2B ρ0 osteosarcoma [18], E3 ρ0 serous
ovarian carcinoma [18], HSA ρ0 cervical cancer [18], and
T47D ρ0 breast cancer [19] cell lines relative to their paren-
tal counterparts.
A549 ρ0 cells do not express mtDNA-derived transcripts in 
culture or in xenografts
We performed quantitative PCR analysis of mtDNA-
encoded MT-ATP6 and MT-CYB transcripts in A549 and
A549 ρ0 cells grown in culture and in xenografts, in the
absence of ethidium bromide. In contrast to the parental
A549 cells, the expression of these two transcripts could
not be detected in ρ0  cells (Additional File 1). This
strongly suggests that, in bulk, the A549 ρ0 cells retained
their mtDNA-depleted genotype over the course of their
growth in culture and in xenograft. This was important to
ascertain since it was possible that during their growth in
xenograft, rare mtDNA-positive cells present in the
injected A549 ρ0 cell population could have substantially
increased in abundance and affected our downstream
analyses. Similarly, it is possible that A549 or A549 ρ0 cells
with certain genetic or epigenetic changes (e.g. those that
confer a growth advantage) were selected for in culture or
in xenografts and affected our results. This should be con-
sidered when interpreting the molecular analyses dis-
cussed below.
Gene expression profiling of cultured cells
Gene expression profiles were generated in plateau phase
A549 and A549 ρ0 cells cultured in fresh medium supple-
mented with pyruvate and uridine prior to RNA isolation
(see Additional File 2 for all data and Additional File 3 forBMC Genomics 2008, 9:521 http://www.biomedcentral.com/1471-2164/9/521
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volcano plot). All 276 transcripts that were differentially
expressed (defined for every pair-wise comparison dis-
cussed hereafter as being > 1.5-fold change, two-tailed
Student's t-test P  < 0.01 (subjected to Benjamini and
Hochberg correction for multiple comparisons), and > 20
unit difference in geometric mean expression scores) are
listed in Additional File 4. These include 131 transcripts
that were more highly expressed in A549 ρ0 cells and 145
that were more highly expressed in A549 cells.
Increased levels of EMT-related transcripts in cultured 
A549 ρ0 cells
To analyze differentially expressed genes in A549 cells and
their mtDNA-depleted ρ0  counterparts, we conducted
Gene Ontology (GO) analyses on transcripts that were
more highly expressed in the A549 ρ0 cells than the paren-
tal cell line (see Additional File 5A for transcript names
and Additional File 2 for data analysis of specific tran-
script). We used stringent criteria (Fisher's exact test P <
0.001 and at least 4 transcripts) for selection of enriched
categories. The enriched categories included those related
to cell adhesion (15 transcripts) and cell motility (4 tran-
scripts). Upon further inspection of the transcripts in
these categories, it became apparent that they reflect tran-
scriptional signatures of the epithelial-mesenchymal tran-
sition (EMT), a developmental process by which
stationary epithelial cells transform into mobile mesen-
chymal cells [35]. EMT can be driven by the activity of the
transcription factor SNAI2, positively regulated by LOXL2
[36], which leads to the over-expression of CDH2, ITGB3,
and VIM. All five genes are over-expressed in the ρ0 cells.
The fact that CDH1 and FGA are also less abundant in the
ρ0 cells further supports the hypothesis that the ρ0 cells
show an increasingly mesenchymal phenotype relative to
their parental counterparts [35]. The above observations
are consistent with prior reports of mtDNA-depleted A549
cells showing increased invasive behavior relative to
parental A549 cells in a Matrigel basement membrane
matrix invasion assay system [12].
Increased metal ion binding and glucuronidation gene 
expression in A549 ρ0 cell cultures
Two enriched GO categories were related to metal ion
binding (LOXL2  and metallothionein family members
MT1H, MT1G, MT1X, and MT2A) and glucuronidation
(including UDP glucuronosyltransferase 1 family mem-
bers). The increased expression of MTF-1 regulated genes
(i.e. metallothioneins) could indicate higher baseline lev-
els of oxidative stress and/or free metals in the ρ0 cells rel-
ative to their parental counterparts [25]. However, it is
noteworthy that several oxidative stress response genes
(e.g. GPX2, GPX3, and GLRX) are under-expressed in these
ρ0 cells. Glucuronidation is a cellular metabolic pathway
in which UDP-glucuronosyltransferases (UGTs) convert
lipophilic compounds, both endogenous and xenobiotic,
into more readily excreted polar products. UGTs catalyze
the transfer of the glucuronate moiety of uridine diphos-
phoglucuronate (UDPGA) to specific substrates, in order
to attain this increased polarity. The observed differen-
tially expressed UGT1A family members have different
substrate specificities and collectively can react with a vari-
ety of endogenous lipophilic molecules, such as fatty
acids and steroids [37-41]. Given that ρ0 skin fibroblasts
have impaired mitochondrial fatty acid β-oxidation [42],
we propose that the increased abundance of glucuronida-
tion-related transcripts in A549 ρ0 cells is a survival mech-
anism to remove excess fatty acids that are normally
metabolized to carbon dioxide and water in functional
mitochondria.
Characterization of cultured A549 and A549 ρ0 cells Figure 1
Characterization of cultured A549 and A549 ρ0 cells. 
(A) Growth rates of A549 and A549 ρ0 cells in culture are 
provided. Experiments were run in triplicate with error bars 
representing ± 1 standard deviation. Doubling times obtained 
from the fitted curves (N = N0ert) were 20.4 and 27.3 hours 
for parental A549 and A549 ρ0 cultures, respectively. (B) The 
oxygen consumption of A549 and A549 ρ0 cultured cells is 
provided. Where indicated, cells were treated with 1 μg/mL 
antimycin A, an inhibitor of the mitochondrial electron trans-
port chain (ETC). Experiments were run in triplicate with 
error bars representing ± 1 standard deviation.
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Expression profiles of HIF-1 responsive transcripts in A549 
ρ0 cells
Next, we focused on identifying key transcription factors
that could account for a significant number of over-
expressed transcripts in A549 ρ0cells. mtDNA-deficient
cells have proven useful for dissecting the role that mito-
chondria play in HIF-mediated responses to oxygen levels
(reviewed by [43]). In fact, increased baseline levels of
HIF-1 activity in cultured ρ0 cell lines have been noted by
others [44,45]. In our A549 ρ0 cells, HIF-1 appeared to be
an excellent candidate given the over-expression of two
well-established downstream genes (VEGFA and BNIP3).
We began our analyses by focusing on a group of 95 probe
sets representing 63 unique HIF-1 responsive genes high-
lighted in a recent comprehensive review [46] (Additional
File 6). While no other HIF-1 responsive genes reached
our statistical criteria for over-expression, four other well-
established HIF-1 regulated transcripts (IGFBP1, IGFBP3,
TF, and PTGS2) were less abundant in the ρ0 cells relative
to their parental cells. This could reflect the influence of
other transcription factors or accessory proteins that regu-
late HIF-1 activity.
The mechanism underlying the differential expression of
HIF-regulated transcripts in mtDNA-deficient cells is
unknown. For example, it has been proposed that a feed-
back loop involving mitochondrial enzymes and citric
acid cycle intermediates leads to HIF-1 stabilization and
tumorigenesis in several inherited forms of cancer caused
by mtDNA mutations [47]. Another possible explanation
might involve insulin-like growth factor signaling which
has been shown to increase HIF-1 levels [48]. Impor-
tantly, the GO category insulin-like growth factor binding
(CYR61, HTRA1 aka PRSS11, IGFBP4, and IGFBP7) was
enriched for transcripts that were more abundant in the ρ0
relative to parental cells (Additional File 5A).
A549 ρ0 cells over-express HIF-1 a protein relative to the 
parental cell line
To explore the mechanistic basis for the observed differen-
tial expression of HIF-responsive transcripts in culture, we
measured the levels of HIF-1α protein in ρ0 and parental
cells by ELISA (Fig. 3A). The background levels of HIF-1α
were found to be 3-fold higher in ρ0 cells compared to the
parental line. HIF-1α levels increased in the parental A549
line following treatment with cobalt acetate or incubation
under hypoxic (1.5% O2) conditions. In A549 ρ0 cells,
HIF-1α levels were increased modestly following cobalt
treatment but did not appear to be changed by hypoxic
treatment. However, the level of HIF-1α protein does not
solely determine its ability to induce gene expression, as
post-transcriptional modifications are also known to
modulate its activity [49].
To further explore the possible functional consequences
of HIF-1 over-expression, we measured the levels of sev-
eral HIF-regulated gene products by Western blot (Fig.
3B). The MT-CO2 product was included in this analysis to
demonstrate the absence of this mtDNA-encoded protein
in A549 ρ0 cells. In accordance with the expression data,
we found that PGK1 and DDIT4 protein levels were
increased in A549 ρ0 cells (Fig. 3B). However, GLUT1 (aka
SLC2A1) protein levels were essentially unchanged in
A549 and A549 ρ0 cells despite the fact that its transcript
was 2.0-fold more abundant (corrected P  = 0.017) in
A549 ρ0 cells. As could be expected, the incubation of
either parental or ρ0 cells in the presence of cobalt or
under hypoxic conditions led to increased levels of these
HIF-regulated proteins. The effect of cobalt was not as sig-
nificant as that of hypoxia under these conditions. These
data demonstrate that although baseline HIF-1 activity is
higher in ρ0 than parental cells, HIF-regulated activity can
be induced further in both cases.
Decreased icosanoid metabolism and cytoskeleton gene 
expression in cultured A549 ρ0 cells
In parallel, we conducted separate GO analyses on tran-
scripts that were less abundant in A549 ρ0 cells (P < 0.001
and at least four probes sets) (Additional File 5B). The
blood pressure regulation (FGB, PTGS2, FGG, and FGA)
and icosanoid metabolism (AKR1C2, PLA2G4A, PTGS2,
and MGST2) GO categories were significantly enriched for
such transcripts. The presence of multiple fibrinogen fam-
ily members in the former category could reflect possible
differences in cell adhesion in ρ0 cells. The icosanoid
metabolism category could relate to the role arachidonic
Growth rates of A549 and A549 ρ0 xenografts Figure 2
Growth rates of A549 and A549 ρ0 xenografts. Median 
tumor volume over time in nude mice bearing tumors 
derived from A549 or A549 ρ0 cells. Tumor volume meas-
urements commenced at an initial average tumor volume of 
155 mm3 and 208 mm3, respectively. Experiments were con-
ducted using six or seven mice per cohort with error bars 
representing ± 1 standard error of the mean (SEM).
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acid plays in the regulation of steroidogenesis and mito-
chondrial membrane permeability. It has been proposed
that ATP generated by oxidative phosphorylation plays a
key role in the generation and export of arachidonic acid
from the mitochondria [50]. Through its role in leukot-
riene metabolism, arachidonic acid mediates the activity
of steroidogenic acute regulatory protein (StAR), a key reg-
ulator of steroidogenesis. In addition, arachidonic acid
can uncouple oxidative phosphorylation and alter mito-
chondrial membrane permeability [51].
The intermediate filament GO category was enriched for
transcripts that were less abundant in ρ0 cells (i.e. KRT8,
KRT19, NEFL, KRT18, and DSP). KRT18 plays a key role in
maintaining the normal morphology of mitochondria
[52]. Interestingly, VIM, another component of interme-
diate filaments shown to support mitochondrial mor-
phology and organization [53], is over-expressed in ρ0
cells. The dysregulation of intermediate filament genes in
ρ0 cells could contribute to their aberrant mitochondrial
morphology and/or represent cellular responses to rescue
mitochondrial organization.
Increased tRNA synthetase, MHC Class I, and lysosome 
gene expression in A549 ρ0 xenografts
Total RNA from A549 or A549 ρ0 tumors (four per cohort)
were also subject to gene expression profiling analysis (see
Additional File 3 for volcano plot). All 948 transcripts that
were differentially expressed are listed in Additional File
7. These include 485 transcripts that were more highly
expressed in the A549 ρ0 tumors and 463 that were more
highly expressed in A549 tumors. Three major functional
categories emerged from GO analyses of over-expressed
genes in ρ0 xenografts (Additional File 8A). These catego-
ries were related to tRNA aminoacylation (composed of 9
tRNA synthetases), MHC class I (B2M, MR1, and six HLA
gene family members), and the lysosome (23 transcripts).
The transcriptional induction of tRNA synthetases was
previously highlighted in the analysis of cultured ρ0 and
parental lymphoblasts [44]. Recently, there is increased
evidence that tRNA synthetases have functions additional
to joining specific amino acids to their cognate tRNAs.
These include the regulation of angiogenesis and inflam-
mation [54,55].
The over-expression of MHC Class I peptides is consistent
with a report that MHC I is over-expressed in fibroblasts
from patients with mtDNA defects as well as in cultured
osteosarcoma ρ0 cells relative to their parental counter-
parts [56]. In that study, IFN-γ treatment enhanced MHC1
over-expression in cultured osteosarcoma ρ0 cells. Thus,
the over-expression of interferon gamma receptor 1
(INFGR1) we observed in A549 ρ0 xenografts (1.8-fold,
corrected P = 0.004) could play a role in further stimulat-
ing MHC Class I peptide expression in these cells.
It has been proposed that MHC Class I over-expression in
cells with mutated mitochondrial proteins provides a
mechanism by which the immune system can recognize
and eliminate defective cells [56]. Although ρ0 cells do not
have dysfunctional proteins encoded by mtDNA, the
over-expression of MHC Class I genes may simply reflect
a mechanism for marking cells with defective mitochon-
drial function.
The over-expression of lysosome genes could relate to
their function in removing defective mitochondria within
cells through autophagy [57]. This could complement the
immune surveillance mediated removal of cells with
defective mitochondria discussed above. We speculate
that the over-expression of lysosome-related genes could
reflect increased numbers of lysosomes and/or simply the
increased functional activity of existing lysosomes.
A549 ρ0 xenograft transcriptomes indicate decreased cell 
proliferation and glycolysis
Mitosis (21 transcripts) and spindle organization and bio-
genesis (9 transcripts) were two major functional catego-
ries showing enrichment for down-regulated transcripts in
A549 ρ0 xenografts (Additional File 8B). This would be
expected given the lower proliferation rate of the A549 ρ0
cells relative to their parental counterparts (Fig. 1A). The
enrichment in the actin binding (21 transcripts) and
cytoskeleton protein binding (27 transcripts) categories
could also reflect differences in growth rates. Alternatively,
they could relate to altered mitochondrial morphology, as
discussed in our analysis of cultured ρ0 cells.
Surprisingly, A549 ρ0  xenografts showed decreased
expression in the glycolysis category (nine transcripts).
This would appear to be counter-intuitive given the fact
that these xenografts do not express mtDNA-derived tran-
scripts (Additional File 1) or MT-COX2 protein (Fig. 3B)
and thus should have severely impaired oxidative phos-
phorylation. Indeed, the 4.7-fold increased abundance of
PCK2 in A549 ρ0cells could indicate higher levels of glu-
coneogenesis, consistent with prior reports in mtDNA-
depleted A549 [12], 206B ρ0osteosarcoma [58], and
ARPE19 ρ0 retinal pigment epithelial [58] cultured cells.
Apart from the aforementioned lower growth rate of ρ0
xenografts, this probably reflects the general reduced
abundance of HIF-regulated transcripts (GAPDH, PKM2,
ENO2, LDHA, EGLN1, SLC2A1, TF, P4HA1, IGF2, CA9,
HIG2, ADM, and EGLN3) as compared to the parental
A549 xenografts (Additional File 6). This occurs despite
the fact that HIF-1α is over-expressed (2.6-fold, P = 1.6 ×
10-4) along with two other well-established HIF targets
(HK1 and BHLHB3). As discussed earlier, this is consistentBMC Genomics 2008, 9:521 http://www.biomedcentral.com/1471-2164/9/521
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with the post-translational control of HIF-1 α activity
(protein modification or subunit localization) and/or the
activity of other transcription factors.
Contribution of mtDNA to gene expression profiles of 
cultured cells and xenografts
While gene expression differences between A549 cells
grown in culture and in xenograft have been reported
[59], comparison for both parental and mtDNA-deficient
cells have not been previously performed. Interestingly, a
greater number of transcripts were differentially expressed
due to growth conditions (culture versus xenograft) than
by mtDNA status. Importantly, infiltrating mouse cells
have been demonstrated not to influence significantly
gene expression profiles of tumor xenografts when using
similar Affymetrix human microarrays [59]. All 2,512
transcripts that were differentially expressed in xenograft
versus culture for the parental A549 line are listed in Addi-
tional File 9. The 2,108 differentially expressed transcripts
for the A549 ρ0 cells grown in xenograft versus culture are
listed in Additional File 10 (see Additional File 3 for vol-
cano plot). These results are borne out by hierarchical
clustering analysis which first shows a clear separation of
the gene expression profiles grown in culture versus
xenograft and then separation according to mtDNA status,
based on gene expression data obtained from 538 probe
sets whose coefficient of variation was greater than 0.10
(Fig. 4).
We calculated the relative fraction of the variance associ-
ated with mtDNA status in the gene expression profiles
from A549 ρ0 and parental A549 cells grown in culture
and in xenografts (Additional File 2). In particular, we
focused on those transcripts for which over 50% of the
Levels of HIF-1α and HIF-1 target proteins in A549 and A549 ρ0 cells Figure 3
Levels of HIF-1α and HIF-1 target proteins in A549 and A549 ρ0 cells. Plateau phase cultures were treated with con-
trol vehicle (mannitol), cobalt acetate (cobalt, 100 μM), or hypoxia (1.5% oxygen atmosphere). (A) Levels of HIF-1α protein 
relative to control vehicle after 4 hours treatment as measured by ELISA. Effect of incubation under hypoxic conditions or with 
cobalt acetate is shown for comparison. Error bars indicate one standard deviation. (B) Representative Western blot showing 
MT-CO2, PGK1, DDIT4, GLUT1, and HSP60 levels in A549 and A549 ρ0 cells. PGK1 and DDIT4 levels were more abundant 
(1.4- and 4.0-fold, respectively) in A549 ρ0 cells relative to A549 cells. In contrast, GLUT1 and HSP60 levels were only margin-
ally changed (1.1- and 1.25-fold less abundant) in A549 ρ0 cells relative to A549 cells. All estimates were made via phorphorim-
aging analysis with HSC70 levels serving as a loading control. Note that MT-CO2 levels could not be detected in any A549 ρ0 
experiment while DDIT4 was expressed at low levels, but could be quantified in normoxic cells.
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variance (Benjamini and Hochberg corrected Bayes mod-
erated F test P < 0.01) could be explained by mtDNA sta-
tus and where there was significant differential expression
in any two of the pair-wise comparisons of A549 ρ0 and
parental A549 cells grown in culture or in xenograft. Over-
all, we discovered 430 transcripts (229 up-regulated and
201 down-regulated in A549 ρ0 relative to the parental
A549 cells) that met these criteria (Additional File 11).
Table 1 provides a listing of a subset of these transcripts
where at least 90% of the variance in gene expression was
dependent upon mtDNA status.
Importantly, the probe set that was most strongly affected
(in this case down-regulated) by mtDNA status measures
the relative abundance of MT-ND5, the only mtDNA-
encoded transcript represented in this microarray (Table
1). MT-ND5 is not expressed in the A549 ρ0 cells in culture
or in xenograft (i.e. ranking within the lowest 15th percen-
tile of all median gene expression scores in both cases).
This provided us with empirical proof that our sorting
strategy was sensitive to detecting transcripts dependent
upon mtDNA status. Overall, we found that the variance
in the expression of transcripts within MHC-1 (6 tran-
scripts) and glucuronidation (4 transcripts) GO categories
are all highly dependent upon mtDNA status (Fig. 5).
These transcripts were more abundant in A549 ρ0 relative
to the parental A549 cells. The MHC-1 and glucuronosyl-
transferase categories were previously discussed as having
significance for the immune surveillance of cells with
effective mitochondria and the detoxification of lipids
that can accumulate due to defects in fatty acid metabo-
lism. On the other hand, transcripts related to the protein
complex assembly (11 transcripts) and chromatin (7 tran-
scripts) GO categories were highly dependent upon
mtDNA status and less abundant in A549 ρ0 cells relative
to the parental A549 cells (Additional File 12). This could
reflect their slower growth rates relative to the parental cell
line.
In addition, mtDNA status affected multiple transcripts
related to the above discussed epithelial-mesenchymal
transition (EMT). Over 50% of the variance in the expres-
sion levels derived from probe sets for the previously
described SNAI2, ITGB3, CDH1, and FGA genes could be
explained by mtDNA status. The expression levels of all
these genes indicated A549 ρ0 cells have increased mesen-
chymal phenotypes relative to the parental A549 cells.
However, the fold-changes in expression of these genes in
ρ0 versus parental cells were greater in culture than in the
tumor xenografts (Additional File 2).
In contrast to genome-wide expression studies performed
in yeast lacking mtDNA (ρ0 petites), we observed no evi-
dence for a strong dependence of the variance in peroxiso-
mal gene expression (especially based on 26 probe sets for
peroxin (PEX) genes responsible for peroxisome assem-
bly) due to mtDNA status [60]. Nevertheless, this does not
preclude mtDNA status affecting peroxisome function,
through abundance and/or activity. For example, we
observed that the mtDNA status had a significant effect on
PHYH expression (explains 76% of the observed variance
in expression, F-test P = 4.56 × 10-4). PHYH encodes a per-
oxisomal enzyme critical for the catabolism of phytanic
acid, a branched chain fatty acid [61,62]. AMACR, which
also encodes an enzyme critical for phytanic acid metabo-
lism, is also expressed higher in A549 ρ0 xenografts rela-
tive to A549 xenografts (2.0-fold, corrected P = 0.007).
Interestingly, AMACR, which localizes to both peroxi-
somes and mitochondria, is an emerging biomarker for
prostate cancer [63]. Given reports of frequent mitochon-
drial defects in prostate cancer [64], it is tempting to spec-
ulate that the over-expression of AMACR in prostate
cancer could be related to defective mitochondrial func-
tion. However, it should be emphasized that the mito-
chondrial defects in our mtDNA-depleted A549 system
will be more severe than those found in human tumors.
mtDNA-dependent expression profiles show agreement 
with prior reports
It can be questioned whether the observed mtDNA-
dependent gene expression profiles are (i) shared
amongst all cell lines, (ii) unique to our system, or (iii)
reflect possible mutations in acquired in the nuclear
genome of the ethidium bromide-treated A549 ρ0 cells. To
begin to address these issues, we searched for previous
reports of differential gene expression in cultured ρ0 cells
relative to their parental cell lines. It is important to note
that there is a limited literature on gene expression profil-
ing in mtDNA-depleted cell cultures [16,44,65,66] and
that there are no previous reports of gene expression pro-
filing in mtDNA-depleted xenografts. Nevertheless, we
found confirmatory evidence for our observed major cat-
egories of mtDNA-dependent transcripts levels including:
tRNA synthetases (over-expressed in osteosarcoma ρ0 cells
[66] and lymphoblastoid ρ0 cells [44]), MHC-related tran-
script (over-expressed in osteosarcoma ρ0 cells [56] and
breast cancer ρ0 cells [65]), UDP-glucuronosyltransferase
(over-expressed in breast cancer ρ0 cells [65]), and HIF1-α
(over-expressed in lymphoblastoid ρ0 cells [44]). Further-
more, the FXY2D2  (aka  ATP1G1) and the VLDR  tran-
scripts, whose levels were strongly dependent upon
mtDNA-status and over-abundant in A549 ρ0 cells (Table
1), were found to be over-expressed in human fibroblasts
with mutations in nuclear-encoded mitochondrial Com-
plex I genes [67] and retinal pigment epithelial ρ0 cells
[14], respectively. Similarly, metallothionein transcripts
were over-expressed in fibroblasts containing mutated
nuclear-encoded mitochondrial genes, in agreement with
our observations in A549 ρ0  cell cultures [67]. Thus,
results from multiple laboratories testing different ρ0 cellBMC Genomics 2008, 9:521 http://www.biomedcentral.com/1471-2164/9/521
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cultures support the assertion that our current analyses at
least partially reflect mtDNA-dependent gene expression
relevant to multiple cell types. Future gene expression pro-
filing experiments of mtDNA-depleted cells generated
using non-chemical-based protocols, such as expressing
siRNA against the TFAM gene [68] or a dominant negative
form of the mitochondria-specific DNA polymerase-
gamma [69], could provide valuable empirical data to
assess our candidate mtDNA-dependent gene expression
profiles. Ultimately, large-scale proteomic characteriza-
tion of mtDNA-depleted and parental cells will be neces-
sary to rigorously assess possible functional consequences
of differential gene expression [15,70].
Contribution of growth conditions to gene expression 
profiles
Next, we calculated the relative fraction of the variance
associated with growth conditions in the gene expression
profiles from ρ0 and parental cells grown in culture and in
xenografts. At first, we focused on those transcripts for
which over 50% of the variance (corrected F test P < 0.01)
could be explained by growth conditions and where there
was differential expression in any of the pair-wise compar-
isons of ρ0 and parental A549 cells grown in culture or in
xenograft. Overall, we uncovered 2,633 transcripts that
met these criteria. In order to reduce transcript complex-
ity, we focused on the subset of 551 transcripts (316 up-
regulated and 235 down-regulated in xenografts relative
Hierarchical clustering analysis of expression data from A549 and A549 ρ0 cells in culture and in xenografts Figure 4
Hierarchical clustering analysis of expression data from A549 and A549 ρ0 cells in culture and in xenografts. 
The dendrograms were generated based on average linkage hierarchical clustering of expression data from 538 probe sets 
whose coefficient of variation was greater than 0.10. Data from A549 cultures are provided in triplicate.
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to cultured cells) where growth conditions contributed to
a robust 90% of the variance observed in the data set
(Additional File 13). Table 2 lists a subset of these tran-
scripts where at least 97% of the variance in gene expres-
sion was dependent upon mtDNA status.
Of the GO categories enriched for transcripts whose
expression was highly dependent upon growth condi-
tions, only the nuclear RNA splicing GO category (9 tran-
scripts) were more abundant in xenografts relative to
cultured cells (Additional File 14A). However, multiple
GO categories were enriched for transcripts whose vari-
ance was principally explained by growth conditions and
were less abundant in xenografts relative to cell culture.
These included categories related to mitochondrial func-
tion (50 mitochondrion transcripts), glycolysis (7 tran-
scripts), electron carrier activity (11 transcripts), purine
Gene Ontology analysis of up-regulated transcripts in ρ0 cells whose variance is strongly influenced by mtDNA status Figure 5
Gene Ontology analysis of up-regulated transcripts in ρ0 cells whose variance is strongly influenced by mtDNA 
status. The directed acyclic graph (DAG) represents the relationships of categories (shown in red) that are enriched for tran-
scripts where mtDNA status accounted for over 50% of the observed variance in gene expression and are more abundant in 
vitro (i.e. cell culture) and/or in vivo (i.e. xenograft) in A549 ρ0 cells relative to parental A549 cells. All 229 probe sets used in 
this analysis are provided in Additional File 11. The names of genes in terminal categories are provided the blue.
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Table 2: Transcripts where 97% of the variance in gene expression is explained by growth conditions
Affymetrix Probe IDa Gene Symbol Entrez GeneID Gene Description Growth Prop. of 
Varianceb
F testc ρ0 Vivo/ρ0 Vitro WT Vivo/WT 
Vivo
FCd Pe FCd Pe
Up-regulated and 
dependent on 
growth conditions
211571_s_at CSPG2 1462 chondroitin sulfate 
proteoglycan 2
0.99 1.41 × 10-12 34.6 0.0001 19.0 0.0002
215646_s_at CSPG2 1462 chondroitin sulfate 
proteoglycan 2
0.99 2.52 × 10-12 33.5 0.0003 20.3 0.0003
220952_s_at PLEKHA5 54477 PI 3-phosphate-binding 
protein-2
0.99 1.79 × 10-11 6.7 0.0003 5.6 0.0006
209090_s_at SH3GLB1 51100 SH3-domain GRB2-like 
endophilin B1
0.99 2.86 × 10-10 3.0 0.0015 3.1 0.0002
216405_at LGALS1 3956 lectin, galactoside-binding, 
soluble, 1
0.98 6.43 × 10-12 11.5 0.0007 14.4 0.0006
212254_s_at DST 667 dystonin 0.98 3.64 × 10-11 3.9 0.0006 4.7 0.0003
201056_at GOLGB1 2804 golgin B1, golgi integral mem. 
protein
0.98 2.12 × 10-10 3.3 0.0008 2.9 0.0004
221829_s_at TNPO1 3842 transportin 1 0.98 2.86 × 10-10 4.0 0.0012 3.9 0.0005
204619_s_at CSPG2 1462 chondroitin sulfate 
proteoglycan 2
0.98 3.01 × 10-11 12.2 0.0003 7.5 0.0003
205173_x_at CD58 965 CD58 molecule 0.98 1.70 × 10-10 3.5 0.0014 3.7 0.0004
218901_at PLSCR4 57088 phospholipid scramblase 4 0.98 1.32 × 10-9 3.5 0.0009 3.8 0.0014
213229_at DICER1 23405 Dicer1, Dcr-1 homolog 0.97 2.18 × 10-10 6.1 0.0009 7.0 0.0013
208772_at ANKHD1 404734 ankyrin repeat & KH domain 
containing 1
0.97 1.97 × 10-9 2.5 0.0027 2.4 0.0003
221731_x_at CSPG2 1462 chondroitin sulfate 
proteoglycan 2
0.97 4.35 × 10-11 104.7 0.0001 30.9 0.0002
201057_s_at GOLGB1 2804 golgin B1, golgi integral mem. 
protein
0.97 1.39 × 10-9 3.2 0.0027 2.9 0.0002
214295_at KIAA0485 57235 KIAA0485 protein 0.97 4.14 × 10-10 3.9 0.0014 4.1 0.0008
201024_x_at EIF5B 9669 eukaryotic translation 
initiation factor 5B
0.97 2.66 × 10-9 2.3 0.0012 2.2 0.0012
201280_s_at DAB2 1601 disabled homolog 2 0.97 4.14 × 10-10 5.3 0.0004 3.5 0.0006
218396_at VPS13C 54832 vacuolar protein sorting 13 
homolog C
0.97 8.54 × 10-10 4.4 0.0012 4.8 0.0006
205383_s_at ZBTB20 26137 zinc finger and BTB domain 
containing 20
0.97 5.52 × 10-10 4.2 0.0011 6.7 0.0003
219221_at ZBTB38 253461 zinc finger and BTB domain 
containing 38
0.97 2.98 × 10-12 6.0 0.0007 6.5 0.0003
208663_s_at TTC3 7267 tetratricopeptide repeat 
domain 3
0.97 1.19 × 10-9 3.1 0.0021 3.1 0.0013
212070_at GPR56 9289 G protein-coupled receptor 
56
0.97 3.78 × 10-10 3.3 0.0007 4.3 0.0008
203216_s_at MYO6 4646 myosin VI 0.97 2.35 × 10-9 3.1 0.0018 2.7 0.0012
204620_s_at CSPG2 1462 chondroitin sulfate 
proteoglycan 2
0.97 6.97 × 10-11 104.5 0.0001 27.8 0.0002B
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212062_at ATP9A 10079 ATPase, Class II, type 9A 0.97 2.73 × 10-9 2.5 0.0002 2.7 0.0030
213775_x_at ZNF638 27332 zinc finger protein 638 0.97 2.86 × 10-10 2.6 0.0008 3.0 0.0005
Down-regulated 
and dependent on 
growth conditions
213201_s_at TNNT1 7138 troponin T type 1 0.99 6.43 × 10-12 -6.9 0.0002 -5.0 0.0003
212432_at GRPEL1 80273 GrpE-like 1, mitochondrial 0.99 1.37 × 10-9 -2.3 0.0008 -2.3 0.0005
209507_at RPA3 6119 replication protein A3, 14 
kDa
0.98 6.76 × 10-10 -2.2 0.0010 -2.3 0.0002
209825_s_at UCK2 7371 uridine-cytidine kinase 2 0.98 1.09 × 10-9 -2.5 0.0019 -2.3 0.0006
202533_s_at DHFR 1719 dihydrofolate reductase 0.98 3.51 × 10-9 -2.1 0.0013 -2.0 0.0006
201577_at NME1 4830 non-metastatic cells 1, 
protein expressed
0.97 2.29 × 10-9 -2.1 0.0014 -2.0 0.0004
208756_at EIF3S2 8668 euk. transl. init. factor 3, 
subunit 2 beta
0.97 1.92 × 10-8 -1.8 0.0002 -1.7 0.0013
207239_s_at PCTK1 5127 PCTAIRE protein kinase 1 0.97 6.29 × 10-9 -1.9 0.0017 -1.9 0.0007
204126_s_at CDC45L 8318 CDC45 cell division cycle 45-
like
0.97 2.31 × 10-8 -2.0 0.0030 -1.9 0.0004
219162_s_at MRPL11* 65003 mitochondrial ribosomal 
protein L11
0.97 1.37 × 10-9 -2.5 0.0010 -2.2 0.0006
208847_s_at ADH5 128 alcohol dehydrogenase 5, chi 
polypeptide
0.97 5.92 × 10-8 -1.7 0.0022 -1.6 0.0007
210250_x_at ADSL 158 adenylosuccinate lyase 0.97 4.04 × 10-9 -2.0 0.0015 -2.3 0.0012
208799_at PSMB5 5693 proteasome beta 5 subunit 0.97 2.6 × 10-8 -1.9 0.0025 -1.8 0.0004
221620_s_at NOMO3 408050 NODAL modulator 3 0.97 1.64 × 10-9 -2.0 0.0015 -2.3 0.0004
210519_s_at NQO1 1728 NAD(P)H dehydrogenase, 
quinone 1
0.97 7.60 × 10-9 -2.1 0.0020 -1.8 0.0007
208910_s_at C1QBP 708 splicing factor SF2-associated 
protein
0.97 1.63 × 10-9 -2.4 0.0020 -2.5 0.0008
201903_at UQCRC1 7384 ubiquinol-cytochrome c 
reductase
0.97 9.25 × 10-9 -1.8 0.0019 -2.1 0.0009
200039_s_at PSMB2 5690 proteasome subunit, beta 
type, 2
0.97 5.72 × 10-9 -1.9 0.0022 -2.0 0.0006
217960_s_at TOMM22 56993 mitochondrial import 
receptor Tom22
0.97 1.04 × 10-8 -2.2 0.0007 -1.9 0.0014
205691_at SYNGR3 9143 synaptogyrin 3 0.97 1.83 × 10-9 -3.1 0.0012 -2.4 0.0012
aOnly probe tilings representing genes with annotated functions are provided
bProportion of variance in gene expression due to growth conditions (i.e. cultured cells or xenografts)
cBayes modified F test (multiple hypothesis corrected)
dFold-change eBenjamini and Hochberg corrected two-tailed Student's t-test
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metabolism (5 transcripts), and the proteosome core
complex (6 transcripts) (Additional File 14B).
The decrease in mitochondrial transcripts encoded by the
nuclear genome may relate to the relative oxygen depriva-
tion in xenografts relative to cell culture which would
cause cells to rely less upon oxidative phosphorylation for
their energy needs. The fact that growth conditions play a
larger role in the expression of nuclear-encoded mito-
chondrial genes than the presence of the mitochondrial
genome is not surprising if one considers the fact that ρ0
cells form mitochondrial structures in the absence of
mtDNA. Furthermore, this is consistent with observations
that there are no differences in the expression of nuclear-
encoded oxidative phosphorylation genes in parental and
mtDNA-deficient osteosarcoma cells [71]. Interestingly,
we could not detect differential transcript levels of nuclear
encoded mtDNA polymerase (POLG), previously
reported to be decreased on the protein level in HeLa ρ0
cells [72], in any pair-wise comparison of experimental
grouping performed in this study. However, we did find
growth conditions accounted for 73% of the variance in
gene expression (corrected F test P = 8.3 × 10-6 and down-
regulated in xenografts) of the nuclear encoded mito-
chondrial RNA polymerase POLRMT, which was reported
to be down-regulated on the protein level in response to
mtDNA depletion in HeLa cells [72].
The above observations, also supported by KEGG (Kyoto
Encyclopedia of Genes and Genomes) pathway analyses
of the same group of transcripts (Additional File 15), indi-
cate that both glycolysis and aerobic respiration-related
genes are less abundant in xenografts relative to culture.
This could relate to the cells being cultured in glucose-rich
medium that does not reflect the situation found in vivo.
In combination, decreased glycolysis and oxidative phos-
phorylation in xenografts reflects lower energetic
demands in vivo. Likewise, the decreased abundance of
transcripts related to purine metabolism in xenografts is
likely related to slower growth rates in xenografts relative
to culture. Decreased purine metabolism could also reflect
the absence of the super-physiological levels of glutamine
present in cell culture media.
Role of mtDNA mutations in human disorders
A549 lung cancer cells provide an appealing model sys-
tem to study mitochondrial function due to their ability to
be grown in culture and in tumor xenografts. The poten-
tial role of mitochondrial function in cancer was first rec-
ognized by Otto Warburg when he observed that cancer
cells show a characteristic shift in energy production from
oxidative phosphorylation to glycolysis [73]. More
recently, there has been increasing appreciation of the
possible importance of inherited and somatic mtDNA
mutations in cancer [74]. Based on the gene expression
profiles observed in this study, ρ0 xenograft tumor models
could be of particular interest in determining mtDNA-
mediated responses to specific cancer therapies, such anti-
angiogenic agents.
In addition, ρ0 cells play a critical role in the production
of cybrid (cytoplasmic hybrid) cell lines containing spe-
cific mutations in mtDNA. While multiple groups have
used this elegant system to study mitochondrial function
in cultured cells (see reviews [4,75]), only recently have
these cybrids been used in tumor xenografts [64]. Gene
expression profiling of such cybrids both in culture and in
xenografts could provide valuable data to elucidate fur-
ther the functional interactions between the nuclear and
mitochondrial genomes.
Conclusion
Although growth conditions had a greater influence on
gene expression profiles than the presence of active mito-
chondria, we identified mtDNA-dependent gene expres-
sion profiles that are shared in cultured A549 cells and in
xenografts. These profiles indicate that cells with mtDNA
alterations have distinct biochemical properties that make
them well-suited for elucidating responses to physiologi-
cal perturbations, such as changes in oxygen and glucose
levels, and testing the effects of specialized classes of
chemotherapeutic agents. In addition, our studies suggest
that gene expression profiling of mtDNA-depleted cells
grown culture and in xenografts provide powerful means
to investigate possible relationships between mitochon-
drial activity and gene expression profiles in normal and
pathological cells.
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